Evidence map›Paper›PMID 40943418›Full record

ReviewInternational journal of molecular sciences2025

Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors.

Ane Arrasate, Carlos Lopez-Robles, Miren Zuazo, Soledad Banos-Mateos, Cesar Martin, Andrés Lamsfus-Calle, Marie J Fertin

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ane ArrasateVIVEbiotech, 20014 Donostia-San Sebastian, Spain.
Carlos Lopez-RoblesVIVEbiotech, 20014 Donostia-San Sebastian, Spain.
Miren ZuazoVIVEbiotech, 20014 Donostia-San Sebastian, Spain.
Soledad Banos-MateosVIVEbiotech, 20014 Donostia-San Sebastian, Spain.
Cesar MartinDepartment of Biochemistry and Molecular Biology, University of the Basque Country UPV/EHU, 48940 Bilbao, Spain.ORCID 0000-0002-4087-8729
Andrés Lamsfus-CalleVIVEbiotech, 20014 Donostia-San Sebastian, Spain.ORCID 0000-0002-4464-0152
Marie J FertinVIVEbiotech, 20014 Donostia-San Sebastian, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extensive studies about the human immunodeficiency virus type 1 (HIV-1) have allowed the generation of lentiviral vectors as gene delivery vehicles with enhanced safety and efficacy features. In this review, several strategies for controlling the molecular mechanisms occurring during the lentiviral vector manufacturing process are presented. Specifically, modifications focused on LVV manufacturing components, such as plasmids or the producer cell line, that enable increased safety, integrity, and potency of the produced LVV, as well as manufacturing efficiency. Considering the stochasticity of the LVV manufacturing process from plasmid transfection until the budding of the virus from the target cell, minimal modifications might have a huge impact on the final LVV yield. Indeed, the extent of a potential impact may vary depending on the specificities of each LVV regarding the particular genetic payload or the envelope protein. Thus, the feasibility of each of the optimizations described herein requires thorough evaluation. The second part of the review examines the potential multi-purpose nature of the LVV. Growing research in the field has enabled the development of new engineered modalities of LVV, expanding their application scope beyond the traditional ex vivo DNA delivery approach. LVVs are becoming a versatile tool for the packaging or delivery of cargo in the form of DNA, RNA, or protein, allowing their use for in vivo approaches, vaccinology, or gene editing, among others.

Indexed as

Genetic VectorsLentivirusAnimalsGene EditingGenetic TherapyGene Transfer TechniquesGenomeHumansCAR-Tex vivo gene therapyHIV-1in vivo gene therapylentiviral vectorsLVV manufacturingRNA deliveryvaccinology

Identifiers

PMID40943418
PMCPMC12429303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.